Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Share-based Compensation (2019 - 2025)

Pulmonx has reported Share-based Compensation over the past 7 years, most recently at $5.2 million for Q3 2025.

  • Quarterly Share-based Compensation rose 638.0% to $5.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Sep 2025, up 77.69% year-over-year, with the annual reading at $23.0 million for FY2024, 3.86% up from the prior year.
  • Share-based Compensation was $5.2 million for Q3 2025 at Pulmonx, down from $6.2 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $6.2 million in Q2 2025 and troughed at $700000.0 in Q2 2024.
  • The 5-year median for Share-based Compensation is $4.4 million (2022), against an average of $4.1 million.
  • Year-over-year, Share-based Compensation skyrocketed 1354.09% in 2021 and then tumbled 88.34% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2021, then surged by 41.0% to $4.2 million in 2022, then skyrocketed by 31.81% to $5.6 million in 2023, then decreased by 1.34% to $5.5 million in 2024, then decreased by 6.46% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Share-based Compensation are $5.2 million (Q3 2025), $6.2 million (Q2 2025), and $5.6 million (Q1 2025).